Retatrutide is an investigational medication designed to treat obesity and related metabolic conditions, such as type 2 diabetes. What makes it unique is its triple-action mechanism: it targets three key hormone receptors—GLP-1, GIP, and glucagon—which are all involved in regulating appetite, energy use, and blood sugar levels. By activating these pathways simultaneously, retatrutide may help reduce hunger, increase feelings of fullness, and boost calorie burning.
Early clinical trials have shown particularly impressive results, with some participants losing a significant percentage of their body weight over the course of treatment—levels that approach those seen with bariatric surgery. In addition to weight loss, the drug has also demonstrated potential benefits in improving blood glucose control and other metabolic markers.
Retatrutide is still undergoing clinical testing and has not yet been approved for general use by regulatory authorities. Researchers continue to study its long-term safety, effectiveness, and potential role in managing obesity and metabolic diseases.
Recommended research dosage: 1-8mg/week